577 related articles for article (PubMed ID: 12871139)
1. Synthetic vaccines: the role of adjuvants in immune targeting.
Jiang ZH; Koganty RR
Curr Med Chem; 2003 Aug; 10(15):1423-39. PubMed ID: 12871139
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
3. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
Xu Z; Moyle PM
Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
Yu C; An M; Li M; Liu H
Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
[TBL] [Abstract][Full Text] [Related]
5. Structural Properties of Potential Synthetic Vaccine Adjuvants - TLR Agonists.
Honegr J; Soukup O; Doležal R; Malinak D; Penhaker M; Prymula R; Kuca K
Curr Med Chem; 2015; 22(29):3306-25. PubMed ID: 26295466
[TBL] [Abstract][Full Text] [Related]
6. Synthetic immunomodulators and synthetic vaccines.
Leclerc C; Vogel FR
Crit Rev Ther Drug Carrier Syst; 1986; 2(4):353-406. PubMed ID: 3103928
[TBL] [Abstract][Full Text] [Related]
7. Lipophilic Muramyl Dipeptide-Antigen Conjugates as Immunostimulating Agents.
Willems MM; Zom GG; Meeuwenoord N; Khan S; Ossendorp F; Overkleeft HS; van der Marel GA; Filippov DV; Codée JD
ChemMedChem; 2016 Jan; 11(2):190-8. PubMed ID: 26059481
[TBL] [Abstract][Full Text] [Related]
8. Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses.
Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Dolzhikova IV; Stanhope-Baker P; Naroditsky BS; Gudkov AV; Logunov DY; Gintsburg AL
PLoS One; 2016; 11(5):e0155650. PubMed ID: 27187797
[TBL] [Abstract][Full Text] [Related]
9. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
10. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
11. Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity.
Azuma I
Vaccine; 1992; 10(14):1000-6. PubMed ID: 1471423
[TBL] [Abstract][Full Text] [Related]
12. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.
Baldridge JR; McGowan P; Evans JT; Cluff C; Mossman S; Johnson D; Persing D
Expert Opin Biol Ther; 2004 Jul; 4(7):1129-38. PubMed ID: 15268679
[TBL] [Abstract][Full Text] [Related]
13. Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery.
Skwarczynski M; Toth I
Methods Mol Biol; 2011; 751():297-308. PubMed ID: 21674338
[TBL] [Abstract][Full Text] [Related]
14. Adjuvants and autoimmunity.
Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y
Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572
[TBL] [Abstract][Full Text] [Related]
15. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.
Marciani DJ
Drug Discov Today; 2003 Oct; 8(20):934-43. PubMed ID: 14554157
[TBL] [Abstract][Full Text] [Related]
16. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
Daubenberger CA
Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
[TBL] [Abstract][Full Text] [Related]
17. Nonpyrogenic Molecular Adjuvants Based on norAbu-Muramyldipeptide and norAbu-Glucosaminyl Muramyldipeptide: Synthesis, Molecular Mechanisms of Action, and Biological Activities in Vitro and in Vivo.
Effenberg R; Turánek Knötigová P; Zyka D; Čelechovská H; Mašek J; Bartheldyová E; Hubatka F; Koudelka Š; Lukáč R; Kovalová A; Šaman D; Křupka M; Barkocziova L; Kosztyu P; Šebela M; Drož L; Hučko M; Kanásová M; Miller AD; Raška M; Ledvina M; Turánek J
J Med Chem; 2017 Sep; 60(18):7745-7763. PubMed ID: 28829599
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of the innate immune system in domestic animals.
Coffey TJ; Werling D
Cell Tissue Res; 2011 Jan; 343(1):251-61. PubMed ID: 20953632
[TBL] [Abstract][Full Text] [Related]
19. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
20. Murabutide revisited: a review of its pleiotropic biological effects.
Jakopin Ž
Curr Med Chem; 2013; 20(16):2068-79. PubMed ID: 23531213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
